Evidence map›Paper›PMID 42281194›Full record

ArticleClinical and translational medicine2026

Super-enhancer-driven KIAA1522 upregulation suppresses ferroptosis in hepatocellular carcinoma.

Xinyang Li, Siyuan Hu, Haolin Shi, Pan Bian, Ziming Wang, Jiachun Sun

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyang LiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Siyuan HuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Haolin ShiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Pan BianHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Ziming WangHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Jiachun SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.

Funding

National Natural Science Foundation of China 81872500the Science and Technology Project of Henan Province 252102310095
6 · The paper itself

Abstract

backgroundAberrantly activated super-enhancers (SEs) drive hepatocellular carcinoma (HCC) malignancy. However, the sustained oncogenic mechanisms mediated by SE-driven genes remain elusive.

methodsHCC-specific SE genes were identified by cross-analysing H3K27ac ChIP-seq and RNA sequencing (RNA-seq). Analyses of HCC databases using Cox proportional hazards regression were performed to identify core SE-activated genes. The SE-mediated transcriptional activation of an identified gene (i.e., KIAA1522) was validated through SE landscapes, ChIP‑qPCR, CRISPR interference and dual‑luciferase reporter assays. HCC cells with knockdown or overexpression of KIAA1522 were constructed to evaluate its functional impact, and RNA-seq was performed to identify downstream pathways. Ferroptosis was evaluated by measuring the levels of malondialdehyde (MDA), reactive oxygen species (ROS) and ferrous ions.

resultsSE inhibitors suppressed HCC cell proliferation. KIAA1522 was identified as an HCC-specific SE gene, exhibiting elevated expression in HCC tissues and an association with unfavourable outcomes. Targeting SEs reduced KIAA1522 expression, and the SE region at chr1: 32753965‒32762956 transcriptionally activated KIAA1522. Functionally, KIAA1522 knockdown exerted anti-proliferative effects in vitro and in vivo. Furthermore, its knockdown triggered ferroptosis, elevated the levels of MDA, ROS and ferrous ions, and downregulated the expression of hallmark proteins. Conversely, KIAA1522 overexpression reversed these effects. Notably, targeting the SEs recapitulated the phenotypic consequences of KIAA1522 knockdown. Mechanistically, activating transcription factor 4 (ATF4) serves as a key downstream effector of KIAA1522, playing an essential role in ferroptosis triggered by KIAA1522 knockdown.

conclusionAs a SE-driven oncogene, KIAA1522 facilitates HCC progression via evasion of ferroptosis, representing an actionable target with potential for clinical translation. KEY POINTS: Aberrantly activated SEs drive the overexpression of the oncogene KIAA1522 in HCC. Targeting SEs and knocking down KIAA1522 facilitate ferroptosis in HCC. As a key downstream effector of KIAA1522, ATF4 plays an essential regulatory role in ferroptosis mediated by the oncoprotein.

Indexed as

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsUp-RegulationAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceSuper Enhancersferroptosishepatocellular carcinomaKIAA1522super‐enhancers

Identifiers

PMID42281194
PMCPMC13260693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.